Development and evaluation of a gentamicin pharmacokinetic model that facilitates opportunistic gentamicin therapeutic drug monitoring in neonates and infants

Antimicrobial Agents and Chemotherapy

Volumn 60, Issue 8, 2016, Pages 4869-4877

  Germovsek, Eva ^a   Kent, Alison ^b   Metsvaht, Tuuli ^c   Lutsar, Irja ^c   Klein, Nigel ^a   Turner, Mark A ^d   Sharland, Mike ^b   Nielsen, Elisabet I ^e   Heath, Paul T ^b   Standing, Joseph F ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b ST GEORGE S HOSPITAL   (United Kingdom)

^c UNIVERSITY OF TARTU   (Estonia)

^d UNIVERSITY OF LIVERPOOL   (United Kingdom)

^e UPPSALA UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; GENTAMICIN; ANTIINFECTIVE AGENT;

ALLOMETRY; ANTIBIOTIC THERAPY; AREA UNDER THE CURVE; ARTICLE; BAYES THEOREM; BODY WEIGHT; COHORT ANALYSIS; COMPARTMENT MODEL; CREATININE BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG MONITORING; EVALUATION STUDY; HUMAN; INFANT; KIDNEY FUNCTION; NEWBORN; NEWBORN INTENSIVE CARE; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; PROSPECTIVE STUDY; FEMALE; MALE; META ANALYSIS; PROCEDURES;

ANTI-BACTERIAL AGENTS; BAYES THEOREM; DRUG MONITORING; FEMALE; GENTAMICINS; HUMANS; INFANT; INFANT, NEWBORN; MALE; PROSPECTIVE STUDIES;

EID: 84979536642     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00577-16     Document Type: Article

References (49)

1. Turner MA, Lewis S, Hawcutt DB, Field D. 2009. Prioritising neonatal medicines research: UK Medicines for Children Research Network scoping survey. BMC Pediatr 9:50. http://dx.doi.org/10.1186/1471-2431-9-50.
2. Cantey JB, Wozniak PS, Sanchez PJ. 2014. Prospective surveillance of antibiotic use in the neonatal intensive care unit: results from the SCOUT Study. Pediatr Infect Dis J http://dx.doi.org/10.1097/INF.0000000000000542.
3. Pacifici GM. 2009. Clinical pharmacokinetics of aminoglycosides in the neonate: a review. Eur J Clin Pharmacol 65:419-427. http://dx.doi.org/10.1007/s00228-008-0599-y.
4. Ramirez MS, Tolmasky ME. 2010. Aminoglycoside modifying enzymes. Drug Resist Updat 13:151-171. http://dx.doi.org/10.1016/j.drup.2010.08.003.
5. Rhodin MM, Anderson BJ, Peters AM, Coulthard MG, Wilkins B, Cole M, Chatelut E, Grubb A, Veal GJ, Keir MJ, Holford NH. 2009. Human renal function maturation: a quantitative description using weight and postmenstrual age. Pediatr Nephrol 24:67-76. http://dx.doi.org/10.1007/s00467-008-0997-5.
6. Kearns GL, Abdel-Rahman SM, Alander SW, Blowey DL, Leeder JS, Kauffman RE. 2003. Developmental pharmacology - drug disposition, action, and therapy in infants and children. N Engl J Med 349:1157-1167. http://dx.doi.org/10.1056/NEJMra035092.
7. Turnidge J. 2003. Pharmacodynamics and dosing of aminoglycosides. Infect Dis Clin North Am 17:503-528. http://dx.doi.org/10.1016/S0891-5520(03)00057-6.
8. Begg EJ, Barclay ML, Kirkpatrick CM. 2001. The therapeutic monitoring of antimicrobial agents. Br J Clin Pharmacol 52(Suppl 1):35S-43S.
9. Dersch-Mills D, Akierman A, Alshaikh B, Yusuf K. 2012. Validation of a dosage individualization table for extended-interval gentamicin in neonates. Ann Pharmacother 46:935-942. http://dx.doi.org/10.1345/aph.1R029.
10. Boyle EM, Brookes I, Nye K, Watkinson M, Riordan FA. 2006. "Random" gentamicin concentrations do not predict trough levels in neonates receiving once daily fixed dose regimens. BMC Pediatr 6:8. http://dx.doi.org/10.1186/1471-2431-6-8.
11. Stickland MD, Kirkpatrick CM, Begg EJ, Duffull SB, Oddie SJ, Darlow BA. 2001. An extended interval dosing method for gentamicin in neonates. J Antimicrob Chemother 48:887-893. http://dx.doi.org/10.1093/jac/48.6.887.
12. Burton ME, Brater DC, Chen PS, Day RB, Huber PJ, Vasko MR. 1985. A Bayesian feedback method of aminoglycoside dosing. Clin Pharmacol Ther 37:349-357. http://dx.doi.org/10.1038/clpt.1985.51.
13. Kelman AW, Thomson AH, Whiting B, Bryson SM, Steedman DA, Mawer GE, Samba-Donga LA. 1984. Estimation of gentamicin clearance and volume of distribution in neonates and young children. Br J Clin Pharmacol 18:685-692. http://dx.doi.org/10.1111/j.1365-2125.1984.tb02530.x.
14. Grasela TH, Ott R, Faix RG. 1985. Population pharmacokinetics of gentamicin in neonates using routine clinical data, abstr B23. Abstr Am So Clin Pharmacol Ther, 86th Annu Meet, San Antonio, Texas, USA.
15. Thomson AH, Way S, Bryson SM, McGovern EM, Kelman AW, Whiting B. 1988. Population pharmacokinetics of gentamicin in neonates. Dev Pharmacol Ther 11:173-179.
16. Jensen PD, Edgren BE, Brundage RC. 1992. Population pharmacokinetics of gentamicin in neonates using a nonlinear, mixed-effects model. Pharmacotherapy 12:178-182.
17. Weber W, Kewitz G, Rost KL, Looby M, Nitz M, Harnisch L. 1993. Population kinetics of gentamicin in neonates. Eur J Clin Pharmacol 44(Suppl 1):S23-S25. http://dx.doi.org/10.1007/BF01428387.
18. Lanao JM, Calvo MV, Mesa JA, Martín-Suárez A, Carbajosa MT, Miguelez F, Domínguez-Gil A. 2004. Pharmacokinetic basis for the use of extended interval dosage regimens of gentamicin in neonates. J Antimicrob Chemother 54:193-198. http://dx.doi.org/10.1093/jac/dkh261.
19. Lingvall M, Reith D, Broadbent R. 2005. The effect of sepsis upon gentamicin pharmacokinetics in neonates. Br J Clin Pharmacol 59:54-61. http://dx.doi.org/10.1111/j.1365-2125.2005.02260.x.
20. García B, Barcia E, Pérez F, Molina IT. 2006. Population pharmacokinetics of gentamicin in premature newborns. J Antimicrob Chemother 58:372-379. http://dx.doi.org/10.1093/jac/dkl244.
21. Nielsen EI, Sandstrom M, Honore PH, Ewald U, Friberg LE. 2009. Developmental pharmacokinetics of gentamicin in preterm and term neonates: population modelling of a prospective study. Clin Pharmacokinet 48:253-263. http://dx.doi.org/10.2165/00003088-200948040-00003.
22. Arenas-Lopez S, Mulla H, Durward A, Tibby SM. 2010. Extended-interval gentamicin: population pharmacokinetics in pediatric critical illness. Pediatr Crit Care Med 11:267-274. http://dx.doi.org/10.1097/PCC.0b013e3181b80693.
23. Fuchs A, Guidi M, Giannoni E, Werner D, Buclin T, Widmer N, Csajka C. 2014. Population pharmacokinetic study of gentamicin in a large cohort of premature and term neonates. Br J Clin Pharmacol http://dx.doi.org/10.1111/bcp.12444.
24. Botha JH, du Preez MJ, Adhikari M. 2003. Population pharmacokinetics of gentamicin in South African newborns. Eur J Clin Pharmacol 59:755-759. http://dx.doi.org/10.1007/s00228-003-0663-6.
25. Heimann G. 1983. Renal toxicity of aminoglycosides in the neonatal period. Pediatr Pharmacol (New York) 3:251-257.
26. Laskin OL, Longstreth JA, Smith CR, Lietman PS. 1983. Netilmicin and gentamicin multidose kinetics in normal subjects. Clin Pharmacol Ther 34:644-650. http://dx.doi.org/10.1038/clpt.1983.227.
27. Valitalo PA, van den Anker JN, Allegaert K, de Cock RF, de Hoog M, Simons SH, Mouton JW, Knibbe CA. 12 March 2015. Novel model-based dosing guidelines for gentamicin and tobramycin in preterm and term neonates. J Antimicrob Chemother http://dx.doi.org/10.1093/jac/dkv052.
28. Nakae S, Yamada M, Ito T, Chiba Y, Sasaki E, Sakamoto M, Tada K, Yamada T, Mori S. 1988. Gentamicin dosing and pharmacokinetics in low birth weight infants. Tohoku J Exp Med 155:213-223. http://dx.doi.org/10.1620/tjem.155.213.
29. Ali AS, Farouq MF, Al-Faify KA. 2012. Pharmacokinetic approach for optimizing gentamicin use in neonates during the first week of life. Indian J Pharmacol 44:36-40. http://dx.doi.org/10.4103/0253-7613.91864.
30. Lannigan R, Thomson AH. 2001. Evaluation of 22 neonatal gentamicin dosage protocols using a Bayesian approach. Paediatr Perinat Drug Ther 4:92-100.
31. Rastogi A, Agarwal G, Pyati S, Pildes RS. 2002. Comparison of two gentamicin dosing schedules in very low birth weight infants. Pediatr Infect Dis J 21:234-240. http://dx.doi.org/10.1097/00006454-200203000-00014.
32. Metsvaht T, Tasa T, Kipper K, Padari H, Ilmoja M, Lutsar I. 2015. Population pharmacokinetics (PK) of gentamicin in term and near-term neonates, abstr WSPID-0499. Abstr World Soc Pediatr Infect Dis (WSPID), 9th World Congr, Rio de Janeiro, Brazil.
33. Jaffe M. 1886. Ueber den Niederschlag, welchen Pikrinsäure in normalem Harn erzeugt und über eine neue Reaction des Kreatinins. Z Physiol Chem 10:391-400.
34. Boeckmann AJ, Beal SL, Sheiner LB. 1999. NONMEM users guide. University of California at San Francisco, San Francisco, CA.
35. Anderson BJ, Holford NH. 2009. Mechanistic basis of using body size and maturation to predict clearance in humans. Drug Metab Pharmacokinet 24:25-36. http://dx.doi.org/10.2133/dmpk.24.25.
36. West GB, Brown JH, Enquist BJ. 1997. A general model for the origin of allometric scaling laws in biology. Science 276:122-126. http://dx.doi.org/10.1126/science.276.5309.122.
37. Germovsek E, Barker CI, Standing JF. 2015. An argument for standardised scaling: comparison of methods for scaling clearance in children, p 24, abstr 3635. Abstr Annu Meet Popul Approach Group Eur, Crete, Greece. www.page-meeting.org/?abstr=3635.
38. Cuzzolin L, Fanos V, Pinna B, di Marzio M, Perin M, Tramontozzi P, Tonetto P, Cataldi L. 2006. Postnatal renal function in preterm newborns: a role of diseases, drugs and therapeutic interventions. Pediatr Nephrol 21:931-938. http://dx.doi.org/10.1007/s00467-006-0118-2.
39. Rudd PT, Hughes EA, Placzek MM, Hodes DT. 1983. Reference ranges for plasma creatinine during the first month of life. Arch Dis Child 58: 212-215. http://dx.doi.org/10.1136/adc.58.3.212.
40. R Core Team. 2014. R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. http://www.R-project.org/.
41. Lindbom L, Pihlgren P, Jonsson EN. 2005. PsN-Toolkit - a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM. Comput Methods Programs Biomed 79:241-257. http://dx.doi.org/10.1016/j.cmpb.2005.04.005.
42. Jonsson EN, Karlsson MO. 1999. Xpose - an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. Comput Methods Programs Biomed 58:51-64.
43. Brendel K, Dartois C, Comets E, Lemenuel-Diot A, Laveille C, Tranchand B, Girard P, Laffont CM, Mentre F. 2007. Are population pharmacokinetic and/or pharmacodynamic models adequately evaluated? A survey of the literature from 2002 to 2004. Clin Pharmacokinet 46:221-234.
44. Sheiner LB, Beal SL. 1981. Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm 9:503-512. http://dx.doi.org/10.1007/BF01060893.
45. Paediatric Formulary Committee. 2016. BNF for children. Pharmaceutical Press, London, United Kingdom.
46. Ambrose PG, Bhavnani SM, Rubino CM, Louie A, Gumbo T, Forrest A, Drusano GL. 2007. Pharmacokinetics-pharmacodynamics of antimicrobial therapy: it's not just for mice anymore. Clin Infect Dis 44:79-86. http://dx.doi.org/10.1086/510079.
47. Prayle A, Watson A, Fortnum H, Smyth A. 2010. Side effects of aminoglycosides on the kidney, ear and balance in cystic fibrosis. Thorax 65: 654-658. http://dx.doi.org/10.1136/thx.2009.131532.
48. Schentag JJ, Jusko WJ. 1977. Renal clearance and tissue accumulation of gentamicin. Clin Pharmacol Ther 22:364-370. http://dx.doi.org/10.1002/cpt1977223364.
49. Wicha SG, Kees MG, Solms A, Minichmayr IK, Kratzer A, Kloft C. 2015. TDMx: a novel Web-based open-access support tool for optimising antimicrobial dosing regimens in clinical routine. Int J Antimicrob Agents 45:442-444. http://dx.doi.org/10.1016/j.ijantimicag.2014.12.010.